- Thinly-traded nano cap Onconova Therapeutics (NASDAQ:ONTX) files a $100M mixed shelf offering.
- The clinical-stage biopharmaceutical firm's lead product is rigosertib. It is being tested as a single agent and in combination with azacitidine and with chemoradiation therapy in patients with myelodysplastic syndromes.
- Prospectus
Onconova files $100M shelf
Recommended For You
More Trending News
About ONTX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ONTX | - | - |
Onconova Therapeutics, Inc. |